Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome
Abstract
Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.Study Design: Cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.001.Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z.…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 35 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.